8-oh-dpat (5-ht1a agonist) attenuates 6-hydroxy- dopamine-induced catalepsy and modulates inflammatory cytokines in rats

objective(s): neuroinflammation in parkinson disease (pd) is associated with glial cells activation and production of different inflammatory cytokines. in this study, we investigated the effect of chronic administration of 8-oh-dpat on 6-ohda-induced catalepsy and levels of inflammatory cytokines in cerebrospinal fluid (csf).   materials and methods: catalepsy was induced by unilateral infusion of 6-ohda (8 μg/2 μl/rat) into the central region of the sabstantia nigra pars compacta (snc) being assessed by the bar-test, 5, 60, 120 and 180 min after intraperitoneal (ip) administration of 8-oh-dpat (5-ht1a receptor agonist; 0.25, 0.5 and 1mg/kg, ip for 10 days). csf samples were collected on the tenth day of 8-oh-dpat administration and analyzed by elisa method to measure levels of tnf-α, il-1β and il-6. results: chronic injection of 8-oh-dpat decreased catalepsy in a dose dependent manner when compared with the control group. the most anti-cataleptic effect was observed at the dose of 1 mg/kg of 8-oh-dpat. levels of tnf-α in csf increased three weeks after 6-ohda injection while there was a significant decrease in tnf-α level of parkinsonian animals treated with 8-oh-dpat (1 mg/kg, ip for 10 days). il-1β and il-6 decreased and increased in parkinsonian rats and in 8-oh-dpat-treated parkinsonian rats, respectively. conclusion: our study indicated that chronic administration of 8-oh-dpat improves catalepsy in 6-ohda-induced animal model of pd and restores central concentration of inflammatory cytokines to the basal levels. 5-ht1a receptor agonists can be suggested as potential adjuvant therapy in pd by modulation of cerebral inflammatory cytokines.